Study S003344

A Phase I, Single-center, Open-Label, Single-Arm, Fixed-Sequence Study to Evaluate the Drug-Drug Interaction of HDM1002 and Metformin, Empagliflozin, Midazolam, Valsartan, and Warfarin in Overweight/Obese Adult Chinese Subjects

ClinicalTrials.gov record

Registration

Registration: NCT07331389
Study type: INTERVENTIONAL
Phase: PHASE1
Masking: NONE
Status: RECRUITING
Enrollment: 111
Start: 2025-09-24
Primary completion: 2026-01-12
Lead sponsor: Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
Conditions: Overweight Subject; Healthy Subjects
Interventions: DRUG:Metformin; DRUG:Empagliflozin; DRUG:Midazolam; DRUG:Valsartan; DRUG:Warfarin; DRUG:HDM1002
Results posted: FALSE

Registered primary outcomes

AUC[0-∞] [through study completion, an average of 11 weeks]
Cmax [through study completion, an average of 11 weeks]
AUC[0-t] [through study completion, an average of 11 weeks]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.